The new homoleptic ate U(III) siloxide [K(18c6)][U(OSi(O(t)Bu)3)4] 2 was prepared in 69% yield by reduction of [U(OSi(O(t)Bu)3)4] 3 with KC8. The reaction of the neutral U(III) siloxide complex [U(OSi(O(t)Bu)3)2(μ-OSi(O(t)Bu)3)]2 1 with adamantyl azide leads to the isolation of the dinuclear U(VI) imido complex [U2(NAd)4(OSi(O(t)Bu)3)4] 4. The X-ray crystal structure shows the presence of a "cation-cation interaction" between the two [U(NAd)2](2+) groups. In contrast the reactions of 2 with the trimethylsilyl and adamantyl azides afford the U(V) imido complexes [K(18c6)][U(NSiMe3)(OSi(O(t)Bu)3)4] 5-TMS and [K(18c6)][U(NAd)(OSi(O(t)Bu)3)4] 5-Ad pure in 48% and 66% yield, respectively. The reaction of 2 with CsN3 in THF at -40 °C yields a mixture of products from which the azido U(IV) complex [K(18c6)][U(N3)(OSi(O(t)Bu)3)4] 7 and the μ-nitrido diuranium(V) complex [KU(μ-N)(OSi(O(t)Bu)3)]2 8 were isolated. The crystal structure of 8 shows the presence of a rare U2N2 core with two nitrido atoms bridging two uranium centers in a diamond-shaped geometry. In contrast, the reaction of 1 with CsN3 affords the diuranium(IV) complex Cs{(μ-N)[U(OSi(O(t)Bu)3)3]2} 9 presenting a nitrido ligand bridging two uranium and one cesium cations. These results show the importance of the coordination environment in the outcome of the reaction of U(III) with azides.
No takes yet. Share an insight, caveat, or question.
Camp et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: